Best Peptides for Bulking: 8 Ranked by Evidence (2026)

4. MK-677 (Ibutamoren) — the oral bulking option

Best for: users who avoid injection and accept the side-effect profile that comes with daily oral dosing.

MK-677 is the only oral compound on this list. Published research describes it activating the same ghrelin receptor as the GHRPs, taken once daily in trial protocols. The Nass et al. 2008 trial reported daily MK-677 producing 1.6 kg fat-free mass gain over 12 months in older adults, with strength not moving significantly over that window. The clinical translation: trial subjects gained mass, but the gains were largely compositional (water retention, fuller-looking muscles, higher scale weight) rather than functional raw-strength.

For a bulk, the appetite boost and the 24-hour GH/IGF-1 elevation profile are both relevant. The trade-offs trials and community sources flag most consistently are noticeable water retention by week 2, sharp appetite increase, and measurable elevation in fasting blood glucose — community sources commonly treat the 8-week and 12-week HbA1c checks as non-negotiable on an extended MK-677 cycle.

Community reports cluster around the trial-documented effects: hunger onset within days, fluid retention in weeks 1-4, and the same glucose drift trial subjects developed.

Deep dive: MK-677 Dosing Guide | MK-677 Peptide Page

Learn more about MK-677 (Ibutamoren)

Dive deeper before comparing vendors

5. Tesamorelin + Ipamorelin (Blend) — the lean-bulk option

Best for: lifters bulking with the leanest possible fat gain and budget flexibility.

Tesamorelin is the most clinically-tested compound on this list — the only GHRH analog with phase III randomized trial data behind it. The Falutz et al. 26-week trial reported daily tesamorelin reducing visceral fat by roughly 15-18% and raising IGF-1 about 80% versus placebo. A follow-up analysis reported tesamorelin also increasing truncal lean muscle area while decreasing intramuscular fat. Paired with ipamorelin's clean GH-release profile, the stack produces the strongest documented body-composition shift on this list.

For a bulk specifically, community sources commonly describe tesa + ipa as the pick when the priority is shifting more of the surplus calories toward lean tissue rather than fat. The trade-off described most often is cost — tesa + ipa is the most expensive stack on this list.

Community reports cluster around three themes: visible waist-tightening within 4-6 weeks even in a surplus, deeper sleep within the first week, and improved between-session recovery. The most common complaint in community sources is occasional injection-site sensitivity attributed to tesamorelin specifically.

Deep dive: Best Tesamorelin + Ipamorelin Vendors | Tesamorelin Dosing Guide

Learn more about Tesamorelin + Ipamorelin

6. Sermorelin + GHRP-6 — the conservative beginner bulk

Best for: users new to GH peptides looking for the gentlest bulking entry point.

Sermorelin was the original synthetic GHRH analog and has the longest clinical track record of any peptide on this list. Published pharmacokinetic data describe a shorter half-life than CJC-1295 — each pulse is smaller per dose. That smaller pulse is also why community sources commonly describe sermorelin as the conservative on-ramp for users new to GH peptides.

Paired with GHRP-6 for appetite support, the stack covers both the pulse rationale and the caloric-intake problem at a lower intensity than CJC-1295 + GHRP-6. Community usage commonly describes this pairing as the older-user, first-time-bulker entry point.

Community reports cluster around subtle sleep improvements, gradual recovery improvements, and a slower body-composition shift over a 12-16 week cycle. Users who later switch from sermorelin to CJC + ipa typically describe a noticeable step up in pulse strength and outcome.

Deep dive: Best Sermorelin Vendors | CJC-1295 vs Sermorelin

Learn more about Sermorelin

7. GHRP-6 (Solo) — the short-term appetite bridge

Best for: users on an existing bulk who need a temporary appetite push during a stall.

Running GHRP-6 without a GHRH analog produces a smaller GH pulse than the paired protocol — the Pandya et al. 1998 study describes GHRP-6 as requiring endogenous GHRH for the full response. Solo GHRP-6 is rarely described as a primary bulk driver in community usage; the more common pattern is a 4-8 week appetite-bridge phase during a bulk where intake has stalled.

Community reports cluster around the appetite signal showing up immediately and the GH-related effects (sleep, fuller-looking muscles) being smaller than the paired version. Community usage as a first-line bulking peptide is rare.

Deep dive: Best GHRP-6 Vendors

Learn more about GHRP-6

8. Follistatin-344 — the experimental myostatin adjunct

Best for: users who've explored a GHRH+GHRP base and want to test a separate muscle pathway.

Follistatin works through different biology than everything else on this list. Published research describes it binding and neutralizing myostatin — a protein the body produces specifically to limit muscle growth. The Kota et al. 2009 nonhuman primate study reported follistatin gene delivery producing durable muscle size and strength increases. The human peptide-injection dataset is limited and shorter-term.

This is genuinely experimental territory. Community usage typically describes follistatin as a 4-week adjunct layered on top of a GHRH+GHRP stack during the middle of a 16-week bulk — a separate lever rather than a replacement for the base. Long-term human safety data remains thin.

Community reports vary widely, which is itself a signal that responses are individual. Users in community sources commonly describe noticeable strength jumps within 2-3 weeks; others run a full vial and self-report no perceived change.

Deep dive: Follistatin-344 Peptide Page | Follistatin-344 Dosing Guide

Learn more about Follistatin-344

How Different Audiences Choose

Community usage and trial-evidence patterns map cleanly onto reader profiles. Here's how the picks above tend to break down across common audiences:

First-time bulkers with normal appetite typically choose CJC-1295 + ipamorelin. Community sources describe it as the most commonly chosen entry point.

Hard gainers who struggle to hit calories commonly pair CJC-1295 with GHRP-6 specifically for the appetite-stimulating effect documented in published research.

Users over 40 looking for the gentlest bulking entry point commonly settle on sermorelin + GHRP-6. Sermorelin has the longest clinical track record on this list and produces the smallest per-dose pulse.

Users who avoid injection are limited to MK-677 (oral) — the only non-injectable on this list with meaningful GH/IGF-1 elevation in published research. The trade-off is the side-effect profile (water retention, appetite, glucose drift) documented in trials.

Lean-bulk-focused users with budget flexibility typically choose tesamorelin + ipamorelin. It has the strongest clinical evidence for combined fat-loss and lean-mass effects of any peptide on this list.

Users on a second or third bulking cycle sometimes layer IGF-1 LR3 over weeks 9-14 of a 16-week GHRH+GHRP base. Community usage describes this as an addition, not a replacement.

Users testing a separate muscle pathway sometimes layer follistatin-344 for 4 weeks mid-cycle. Community usage describes follistatin as experimental and rarely a first-cycle choice.

For the cutting counterpart, see Best Peptides for Cutting.

What Trial and Community Data Describe as Signals of Effect

Three signals appear consistently in published research and community sources, in this order:

Weeks 1-2: Sleep and recovery first. Community reports cluster around deeper sleep within 2-3 days of starting a GHRH+GHRP bulk base, and faster recovery between training sessions by the end of week 2. Trial subjects describe the same pattern. Absence of any sleep shift by day 14 is what community sources typically flag as a signal of under-dosing or product degradation.

Weeks 4-8: Bloodwork and visible fullness. IGF-1 is the most-tracked biomarker in both trials and community protocols — published research describes a working GHRH+GHRP stack raising IGF-1 30-60% from baseline. Community sources describe under-30% increases as a signal of under-dosing or product issues, and over-60% increases as the dose-reduction threshold most clinical protocols use. Trials also commonly tracked fasting glucose and HbA1c at 8-12 weeks because GH opposes insulin, and a subset of trial subjects developed measurable glucose elevation over time.

Weeks 8-16: Body composition. Trial-reported lean-tissue gains in trained subjects on a full secretagogue cycle have typically clustered around 2-4 lb. Community reports across full 16-week bulking cycles commonly describe 4-7 lb of lean tissue plus 3-5 lb of fat in trained users on a 300-500 kcal surplus, and 6-9 lb of lean mass when IGF-1 LR3 is layered for the final 4-6 weeks. Trial data does not support claims of steroid-scale transformations from secretagogue stacks alone.

Running GH peptides without bloodwork is functionally running them blind. The trial-and-community standard is baseline IGF-1 plus a 4-week recheck and 8-12 week metabolic panel — that's how published research designs measured efficacy, and it's what community sources commonly treat as the minimum monitoring set.

Related Reading

Best Peptides for Muscle Growth — anchor stack ranking

Best Peptides for Cutting — the counterpart article

Beginner Peptide Stack for Muscle — first-cycle setup

Peptide Muscle Timeline — week-by-week expectations

Peptides for Strength vs Mass — goal-based compound choice

GHRP-2 vs GHRP-6 — appetite-GHRP comparison

IGF-1 LR3 Dosing Guide — advanced protocol detail

Peptide Coupons — Save Up to 50%

Exclusive discount codes — save up to 50% at top vendors

References

1

Bowers CY, et al. GH-releasing peptide acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982.

2108187

2

Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805.

16352683

3

Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.

9849822

4

Pandya N, et al. GHRP-6 requires endogenous hypothalamic GHRH for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189.

9543138

5

Nass R, et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;149(9):601-611.

18981485

6

Falutz J, et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. J Clin Endocrinol Metab. 2010;95(9):4291-4304.

20101189

7

Adrian S, et al. Tesamorelin decreases muscle fat and increases muscle area in adults with HIV. J Frailty Aging. 2019;8(3):154-159.

31237318

8

Kota J, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6ra15.

20368179